ASCO 2019 | MRD testing in AML: the next steps in 2019
Michael Heuser
• 1 Jun 2019
Measurable residual disease (MRD) has proved to have potential in testing for hematological malignancies including acute myeloid leukemia (AML). Here, Michael Heuser, MD, of Hannover Medical School, Hanover, Germany, delivers the next steps going forward in MRD testing in 2019. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
